Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004870 · ClinicalTrials.gov registry record · Phase 1
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004870 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio.
The verdict
NCT00004870, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan in treating patients who have metastatic or recurrent colorectal cancer.
Interventions
- DRUG irinotecan hydrochloride
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2002-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004870
The ClinicalTrials.gov registry entry for NCT00004870 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00004870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004870 about?
NCT00004870 is a clinical study titled "Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial...
What is the current status of trial NCT00004870?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-06. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00004870?
The interventions under investigation include: irinotecan hydrochloride (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004870?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.